KWON YOUNG 4

What Happened

• Director Kwon Young was granted equity awards by ADMA BIOLOGICS on February 9, 2026. The filing shows two acquisitions: 10,690 restricted stock units (RSUs) and 17,730 derivative awards (options/other derivative awards), all reported at $0. No cash was paid — these are compensation awards, not open-market purchases.

Key Details

• Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (appears timely).
• Grants: 10,690 RSUs (reported as an award) and 17,730 derivative awards (reported as an award/derivative).
• Reported price: $0.00 (typical for compensation grants; market value depends on ADMA’s share price).
• Shares/units reported after the transaction (per footnote): 246,885 shares of common stock owned, 10,690 RSUs newly granted (vest Feb 9, 2027 per F2), and 5,445 RSUs from a 2025 grant that vest Feb 19, 2026 — totaling 263,020 shares/RSUs counted in the filing; plus 17,730 derivative awards that vest under a separate schedule.
• Vesting notes: The 10,690 RSUs vest in two equal installments (6- and 12-month anniversaries) and become fully vested after one year (F1/F2). The 17,730 derivative awards vest monthly over 12 months, fully vesting after one year (F3).
• No indication of a 10b5-1 plan, sale, tax withholding, or late filing in this Form 4.

Context

• These are compensation awards, not open-market purchases or sales. Grants at $0 are standard for RSU/option awards; their realized value depends on ADMA’s future share price and the recipient’s continued service through vesting dates.
• For retail investors, awards to directors signal management/board compensation alignment with shareholders but are routine and do not by themselves indicate insider buying or selling sentiment.